Patents by Inventor Jorge Agustín AGUIAR SANTIAGO

Jorge Agustín AGUIAR SANTIAGO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11759517
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: September 19, 2023
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Enrique Iglesias Perez, Eduardo Pentón Arias, Gerardo Enrique Guillén Nieto, Jorge Agustin Aguiar Santiago, Sonia Gonzalez Blanco, Jorge Valdes Hernandez, Mariela Vazquez Catillo
  • Patent number: 11491218
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 8, 2022
    Assignee: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA
    Inventors: Julio César Aguilar Rubido, Yadira Lobaina Mato, Enrique Iglesias Perez, Eduardo Pentón Arias, Gerardo Enrique Guillén Nieto, Jorge Agustín Aguiar Santiago, Sonia Gonzalez Blanco, Jorge Valdes Hernandez, Mariela Vazquez Castillo
  • Publication number: 20200297840
    Abstract: This invention reveals the pharmaceutical composition that includes the surface antigen (HBsAg) of the hepatitis B virus (HBV) and the antigen of the nucleocapsid (or core, HBcAg) of the same virus. The HBcAg of this composition contains messenger ribonucleic acid (mRNA) at a proportion of over 45% of the total amount of ribonucleic acid (RNA) in this antigen. Because of the changes in the constitution of the antigens forming it, the composition of the invention is useful for the prevention or treatment of chronic hepatitis B. It also covers the use of this pharmaceutical composition in the production of a drug for immuno-prophylaxis or immunotherapy against HBV infection, and its use to increase the immune response against an additional antigen that is co-administered with the mixture of these antigens.
    Type: Application
    Filed: March 14, 2017
    Publication date: September 24, 2020
    Inventors: Julio César AGUILAR RUBIDO, Yadira LOBAINA MATO, Enrique IGLESIAS PEREZ, Eduardo PENTÓN ARIAS, Gerardo Enrique GUILLÉN NIETO, Jorge Agustín AGUIAR SANTIAGO, Sonia GONZALEZ BLANCO, Jorge VALDES HERNANDEZ, Mariela VAZQUEZ CASTILLO